-

2019 Update of Upstream Medical Technologies Ltd - Product Pipeline Analysis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Upstream Medical Technologies Ltd - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.

Summary

Upstream Medical Technologies Ltd (UMT) is a biomarker based testing developer that markets novel biomarkers for cardiac diagnosis. The company offers patented pipeline of products such as BNP-sp, used for diagnoses of unstable angina, CVD, ACS, and others. It provides pipe line product such as Ghr-sp-Pne diagnoses heart failure in the presence of pneumonia; and EPO-sp for detection of kidney failure. It offers products to identify comorbid disease associated with kidney failure, metabolic disease, sepsis and atrial fibrillation, among others. The company develops biomarker-based testing for diagnoses of heart disease and associated clinical complications. UMT is headquartered in Christchurch, New Zealand.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Upstream Medical Technologies Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

  • Upstream Medical Technologies Ltd Company Overview
  • Upstream Medical Technologies Ltd Company Snapshot
  • Upstream Medical Technologies Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Upstream Medical Technologies Ltd - Pipeline Analysis Overview
  • Upstream Medical Technologies Ltd - Key Facts
  • Upstream Medical Technologies Ltd - Major Products and Services
  • Upstream Medical Technologies Ltd Pipeline Products by Development Stage
  • Upstream Medical Technologies Ltd Pipeline Products Overview
  • CNP-sp Test - Heart Disease
  • CNP-sp Test - Heart Disease Product Overview
  • CRP-sp Assay - Heart Failure
  • EPO-sp Test
  • GH Assay - Heart Failure
  • Ghr-sp Test - Heart Disease
  • Ghr-sp-Pne Test - Heart Failure
  • IGFs Assay - Heart Failure
  • INS-sp Test - Heart failure
  • KIM-1sp Assay - Heart Failure
  • NGAL-sp Test - Heart Failure
  • PSA-sp Assay - Heart Failure
  • TnTuORF Test - Heart Failure
  • TSH Assay - Heart Failure
  • UARatio Test - Angina
  • Upstream Medical Technologies Ltd - Key Competitors
  • Upstream Medical Technologies Ltd - Key Employees
  • Upstream Medical Technologies Ltd - Locations And Subsidiaries
  • Head Office
  • Recent Developments
  • Upstream Medical Technologies Ltd, Recent Developments
  • May 15, 2017: Upstream Medical Technologies Provides Update on UARatio Test - Angina
  • Jul 08, 2016: Upstream Medical Technologies: Dr Jim Januzzi accepts appointment to Scientific Advisory Board
  • Jun 02, 2016: Professor Mark Richards accepts appointment to Scientific Advisory Board of Upstream Medical Technologies
  • Oct 28, 2015: Breakthrough Medical Research Company Formed
  • Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer

Companies Mentioned

  • Jackson Allison Medical & Surgical Ltd
  • Caldera Health Ltd
  • AROTEC Diagnostics Ltd

For more information about this company profile visit https://www.researchandmarkets.com/r/mmb2vj

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Hexabromocyclododecane (CAS 25637-99-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hexabromocyclododecane (CAS 25637-99-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Hexabromocyclododecane provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a v...

Commercial Gas Rice Cookers Market Report 2026: Revenues Set to Reach $2 Billion by 2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Commercial Gas Rice Cookers Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Commercial Gas Rice Cookers Market is experiencing significant growth, evolving from USD 1.28 billion in 2025 to an anticipated USD 2.00 billion by 2032, driven by a CAGR of 6.52%. This market research report provides a comprehensive analysis of the commercial gas rice cooker sector, highlighting key drivers like foodservice efficiency, industria...

Artemisinin Combination Therapy Market to Grow by $194 Million During 2026-2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Artemisinin Combination Therapy Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Artemisinin Combination Therapy (ACT) market exemplifies dynamic growth and promising potential in the treatment of malaria. Expected to increase from USD 386.40 million in 2025 to USD 608.26 million by 2032, supported by a steady CAGR of 6.69%, this market highlights the evolving landscape for modern antimalarial solutions. At the core of AC...
Back to Newsroom